CNBX Pharmaceuticals Inc. (CNBX)
CNBX is quoted over the counter, not listed on an exchange. CNBX Pharmaceuticals Inc. files reports with the SEC; the numbers below come from SEC filings and from daily closes, each with its source.
Closes: Yahoo Finance daily closes, last bar 2026-11-13.
Profile
| Field | Value |
|---|---|
| Ticker | CNBX, quoted over the counter |
| SEC CIK | 0001343009 |
| OTC Markets tier | OTCID (price source, 2026-11-13) |
| SEC industry code | Pharmaceutical Preparations |
| Business address | Bethesda, MD |
| Incorporated in | NV |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "These conditions raise substantial doubt about the ability of the Company to continue as a going concern." | 10-Q 2026-06-24 |
| Cash and burn | $9K cash; operating cash flow -$39K a quarter. | Report 2026-05-31 |
| Shares outstanding | 1,605,768,095 (2026-06-17); 92,511,352 a year earlier; 17,033,732 three years earlier. | Cover page 2026-06-17 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Elkana Amitai CPA, Mizpeh Netofa, Israel; changed auditors 1 time in 24 months | 8-K 4.01 2026-10-01 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-05-31 | $0 | -$154K | -$48K | $9K | $1.2M | $0 | 10-Q 2026-06-24 |
| Q2 2026 2026-02-28 | $0 | -$44K | -$31K | $12K | $1.2M | $0 | 10-Q 2026-04-14 |
| Q1 2026 2025-11-30 | $0 | -$114K | -$47K | $8K | $1.2M | $0 | 10-Q 2026-01-14 |
| Q4 2025 2025-08-31 | $0 | -$150K | -$29K | $15K | $1.2M | $0 | 10-K 2025-12-01 |
| Q3 2025 2025-05-31 | $0 | -$60K | -$52K | $14K | $1.3M | $0 | 10-Q 2026-06-24 |
| Q2 2025 2025-02-28 | $0 | -$70K | -$52K | $46K | $1.4M | $0 | 10-Q 2026-04-14 |
| Q1 2025 2024-11-30 | $0 | -$34K | -$39K | $17K | $1.3M | $41K | 10-Q 2026-01-14 |
| Q4 2024 2024-08-31 | $0 | -$61K | -$48K | $26K | $2.6M | $130K | 10-K 2025-12-01 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-1 | 2022-02-18 |
| Latest annual report | 10-K | 2025-12-01 |
| Latest quarterly / interim | 10-Q | 2026-06-24 |
| Latest current report | 8-K | 2026-10-01 |
Source: SEC EDGAR submissions feed, 302 recent filings. All filings on EDGAR.
The full dossier has every filing, quarterly and annual financials, the health record and a price chart.
Open the full dossier